| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ovarian Neoplasms | 21 | 2013 | 443 | 1.620 |
Why?
|
| Biopsy, Fine-Needle | 2 | 2014 | 106 | 0.730 |
Why?
|
| Carcinoma | 5 | 2012 | 279 | 0.600 |
Why?
|
| Adenocarcinoma | 6 | 2022 | 972 | 0.540 |
Why?
|
| Breast Neoplasms | 10 | 2023 | 2587 | 0.500 |
Why?
|
| Neoplasms, Connective and Soft Tissue | 1 | 2015 | 3 | 0.480 |
Why?
|
| Chondrosarcoma | 1 | 2015 | 13 | 0.480 |
Why?
|
| Foot Diseases | 1 | 2015 | 21 | 0.470 |
Why?
|
| Fibroma | 1 | 2015 | 29 | 0.470 |
Why?
|
| Ovary | 7 | 2010 | 358 | 0.440 |
Why?
|
| Carcinoma, Endometrioid | 4 | 2011 | 16 | 0.430 |
Why?
|
| Bronchoscopy | 1 | 2014 | 179 | 0.410 |
Why?
|
| Ultrasonography, Interventional | 1 | 2014 | 199 | 0.390 |
Why?
|
| Endoscopy | 1 | 2014 | 280 | 0.380 |
Why?
|
| Lung Neoplasms | 3 | 2021 | 1494 | 0.380 |
Why?
|
| Thyroid Neoplasms | 1 | 2014 | 241 | 0.360 |
Why?
|
| Immunohistochemistry | 12 | 2018 | 1601 | 0.360 |
Why?
|
| Breast Neoplasms, Male | 1 | 2009 | 17 | 0.310 |
Why?
|
| Cell Transformation, Neoplastic | 5 | 2012 | 606 | 0.300 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2010 | 185 | 0.290 |
Why?
|
| beta Catenin | 1 | 2009 | 206 | 0.280 |
Why?
|
| MutS Homolog 2 Protein | 2 | 2006 | 39 | 0.270 |
Why?
|
| Barrett Esophagus | 2 | 2022 | 346 | 0.260 |
Why?
|
| Biomarkers, Tumor | 9 | 2013 | 1562 | 0.260 |
Why?
|
| Esophageal Neoplasms | 2 | 2022 | 370 | 0.260 |
Why?
|
| Epithelial Cells | 6 | 2016 | 873 | 0.260 |
Why?
|
| Microsatellite Instability | 1 | 2006 | 36 | 0.250 |
Why?
|
| Oncogene Protein p21(ras) | 1 | 2006 | 11 | 0.240 |
Why?
|
| Tissue Array Analysis | 7 | 2011 | 135 | 0.230 |
Why?
|
| Adenocarcinoma, Mucinous | 4 | 2013 | 39 | 0.220 |
Why?
|
| Tissue Embedding | 1 | 2004 | 3 | 0.220 |
Why?
|
| Cystadenocarcinoma, Serous | 4 | 2013 | 46 | 0.220 |
Why?
|
| Tumor Microenvironment | 2 | 2021 | 627 | 0.210 |
Why?
|
| Influenza, Human | 1 | 2010 | 674 | 0.210 |
Why?
|
| Microscopy | 1 | 2024 | 123 | 0.200 |
Why?
|
| Lung | 1 | 2010 | 1524 | 0.190 |
Why?
|
| Neoplasm Staging | 7 | 2018 | 1291 | 0.190 |
Why?
|
| Telomerase | 4 | 2012 | 153 | 0.190 |
Why?
|
| Adenocarcinoma, Clear Cell | 4 | 2013 | 25 | 0.190 |
Why?
|
| Carrier Proteins | 2 | 2006 | 1011 | 0.180 |
Why?
|
| Prognosis | 8 | 2023 | 4804 | 0.180 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2023 | 317 | 0.180 |
Why?
|
| Veterans | 3 | 2022 | 1744 | 0.180 |
Why?
|
| Sensitivity and Specificity | 3 | 2014 | 2081 | 0.170 |
Why?
|
| Receptors, Estrogen | 5 | 2008 | 714 | 0.170 |
Why?
|
| Nuclear Proteins | 2 | 2006 | 1206 | 0.170 |
Why?
|
| Humans | 45 | 2024 | 127519 | 0.170 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2008 | 1932 | 0.170 |
Why?
|
| Cell Degranulation | 1 | 2020 | 26 | 0.170 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 1 | 2020 | 29 | 0.160 |
Why?
|
| Precancerous Conditions | 2 | 2022 | 278 | 0.160 |
Why?
|
| Duodenum | 1 | 2020 | 110 | 0.160 |
Why?
|
| Female | 35 | 2023 | 68775 | 0.160 |
Why?
|
| Eosinophils | 1 | 2020 | 123 | 0.160 |
Why?
|
| Dyspepsia | 1 | 2020 | 108 | 0.160 |
Why?
|
| Carcinoma, Transitional Cell | 2 | 2013 | 179 | 0.150 |
Why?
|
| Eosinophilia | 1 | 2020 | 105 | 0.150 |
Why?
|
| Middle Aged | 17 | 2020 | 27894 | 0.150 |
Why?
|
| Aged, 80 and over | 9 | 2018 | 6718 | 0.150 |
Why?
|
| Sulfur-Reducing Bacteria | 1 | 2018 | 2 | 0.150 |
Why?
|
| Neoplasms, Glandular and Epithelial | 2 | 2012 | 44 | 0.150 |
Why?
|
| Adult | 17 | 2020 | 30611 | 0.150 |
Why?
|
| Colitis, Microscopic | 1 | 2018 | 15 | 0.140 |
Why?
|
| Thrombocytopenia | 1 | 2020 | 222 | 0.140 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2021 | 439 | 0.140 |
Why?
|
| Aged | 14 | 2020 | 20519 | 0.140 |
Why?
|
| Interleukin-17 | 1 | 2018 | 124 | 0.130 |
Why?
|
| CELF1 Protein | 1 | 2016 | 29 | 0.130 |
Why?
|
| Fibrin | 1 | 2016 | 64 | 0.120 |
Why?
|
| Genes, Tumor Suppressor | 2 | 2007 | 198 | 0.120 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2016 | 238 | 0.110 |
Why?
|
| Oncolytic Viruses | 1 | 2016 | 75 | 0.110 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 363 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 376 | 0.110 |
Why?
|
| Cell Movement | 3 | 2016 | 852 | 0.110 |
Why?
|
| Image-Guided Biopsy | 1 | 2014 | 41 | 0.110 |
Why?
|
| Disease-Free Survival | 3 | 2014 | 900 | 0.110 |
Why?
|
| Nephrotic Syndrome | 2 | 2005 | 50 | 0.110 |
Why?
|
| Polyethylene Glycols | 1 | 2016 | 240 | 0.110 |
Why?
|
| RNA, Small Interfering | 5 | 2008 | 662 | 0.110 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2010 | 1232 | 0.110 |
Why?
|
| Mice, Nude | 4 | 2012 | 708 | 0.100 |
Why?
|
| Neoplasm, Residual | 1 | 2014 | 131 | 0.100 |
Why?
|
| Reproducibility of Results | 2 | 2014 | 2893 | 0.100 |
Why?
|
| Oncogenes | 1 | 2014 | 162 | 0.100 |
Why?
|
| CA-125 Antigen | 1 | 2013 | 13 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2014 | 1055 | 0.100 |
Why?
|
| Adenoviridae | 1 | 2016 | 573 | 0.100 |
Why?
|
| Homeodomain Proteins | 2 | 2007 | 539 | 0.100 |
Why?
|
| Male | 11 | 2020 | 62900 | 0.100 |
Why?
|
| Models, Biological | 2 | 2016 | 1374 | 0.100 |
Why?
|
| Hemorrhage | 2 | 2020 | 492 | 0.100 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2018 | 743 | 0.090 |
Why?
|
| Cost-Benefit Analysis | 1 | 2014 | 535 | 0.090 |
Why?
|
| Endometrial Neoplasms | 1 | 2013 | 108 | 0.090 |
Why?
|
| Cell Line, Tumor | 7 | 2016 | 3503 | 0.090 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2014 | 415 | 0.090 |
Why?
|
| Feasibility Studies | 1 | 2014 | 799 | 0.090 |
Why?
|
| Fallopian Tubes | 1 | 2012 | 73 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2014 | 477 | 0.090 |
Why?
|
| Biopsy | 2 | 2018 | 1237 | 0.090 |
Why?
|
| Carcinogenesis | 1 | 2014 | 344 | 0.090 |
Why?
|
| BRCA2 Protein | 1 | 2011 | 50 | 0.090 |
Why?
|
| DNA Damage | 1 | 2014 | 498 | 0.090 |
Why?
|
| Cell Line, Transformed | 2 | 2012 | 156 | 0.090 |
Why?
|
| Mice | 10 | 2023 | 17695 | 0.090 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2008 | 86 | 0.090 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2018 | 796 | 0.080 |
Why?
|
| Tracheitis | 1 | 2010 | 14 | 0.080 |
Why?
|
| Autopsy | 1 | 2010 | 113 | 0.080 |
Why?
|
| Diagnosis, Differential | 1 | 2015 | 1868 | 0.080 |
Why?
|
| Necrosis | 1 | 2010 | 192 | 0.080 |
Why?
|
| Disease Progression | 3 | 2022 | 2125 | 0.080 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2023 | 130 | 0.080 |
Why?
|
| Mitotic Index | 1 | 2009 | 17 | 0.080 |
Why?
|
| Autophagy | 2 | 2014 | 405 | 0.080 |
Why?
|
| Transfection | 3 | 2007 | 948 | 0.080 |
Why?
|
| Peritoneum | 1 | 2010 | 37 | 0.080 |
Why?
|
| Pulmonary Alveoli | 1 | 2010 | 137 | 0.080 |
Why?
|
| Antigens, CD | 1 | 2011 | 415 | 0.080 |
Why?
|
| Glycoproteins | 1 | 2011 | 338 | 0.080 |
Why?
|
| MutL Protein Homolog 1 | 2 | 2006 | 52 | 0.080 |
Why?
|
| Bronchiolitis | 1 | 2010 | 122 | 0.080 |
Why?
|
| Carcinoma, Papillary | 1 | 2010 | 90 | 0.080 |
Why?
|
| Kidney Transplantation | 2 | 2005 | 560 | 0.080 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2009 | 41 | 0.070 |
Why?
|
| Animals | 12 | 2023 | 33214 | 0.070 |
Why?
|
| Annexin A1 | 1 | 2008 | 5 | 0.070 |
Why?
|
| Isoenzymes | 1 | 2009 | 215 | 0.070 |
Why?
|
| Gene Expression Regulation | 1 | 2016 | 2314 | 0.070 |
Why?
|
| RNA, Viral | 1 | 2010 | 511 | 0.070 |
Why?
|
| Retrospective Studies | 7 | 2022 | 17083 | 0.070 |
Why?
|
| Breast | 1 | 2009 | 208 | 0.070 |
Why?
|
| Peptides | 1 | 2011 | 830 | 0.070 |
Why?
|
| Proteinuria | 2 | 2005 | 105 | 0.070 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2007 | 590 | 0.070 |
Why?
|
| Prospective Studies | 2 | 2016 | 6251 | 0.070 |
Why?
|
| Cell Membrane | 1 | 2009 | 450 | 0.070 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2007 | 50 | 0.070 |
Why?
|
| Cell Nucleus | 1 | 2009 | 552 | 0.070 |
Why?
|
| Gene Products, env | 1 | 2007 | 16 | 0.070 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2013 | 1239 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 3 | 2016 | 637 | 0.060 |
Why?
|
| Gene Expression | 2 | 2008 | 1487 | 0.060 |
Why?
|
| Endogenous Retroviruses | 1 | 2007 | 17 | 0.060 |
Why?
|
| Receptors, Progesterone | 2 | 2008 | 666 | 0.060 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2006 | 13 | 0.060 |
Why?
|
| Tumor Suppressor Protein p14ARF | 1 | 2006 | 12 | 0.060 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 5 | 1 | 2006 | 7 | 0.060 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 2 | 1 | 2006 | 11 | 0.060 |
Why?
|
| Phosphoproteins | 1 | 2008 | 420 | 0.060 |
Why?
|
| Retinoblastoma Protein | 1 | 2006 | 76 | 0.060 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2006 | 73 | 0.060 |
Why?
|
| Antigens, Viral, Tumor | 1 | 2006 | 44 | 0.060 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2006 | 110 | 0.060 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2008 | 579 | 0.060 |
Why?
|
| Acetyltransferases | 1 | 2005 | 72 | 0.060 |
Why?
|
| Prostatic Hyperplasia | 1 | 2006 | 114 | 0.060 |
Why?
|
| Survival Rate | 4 | 2013 | 2111 | 0.060 |
Why?
|
| CpG Islands | 1 | 2007 | 332 | 0.060 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2006 | 584 | 0.060 |
Why?
|
| Signal Transduction | 3 | 2014 | 4489 | 0.060 |
Why?
|
| Comorbidity | 1 | 2010 | 1563 | 0.060 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2006 | 68 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2007 | 332 | 0.060 |
Why?
|
| Oncogene Proteins | 1 | 2005 | 133 | 0.060 |
Why?
|
| Simian virus 40 | 1 | 2006 | 190 | 0.060 |
Why?
|
| Mullerian Ducts | 1 | 2005 | 46 | 0.060 |
Why?
|
| Biomarkers | 2 | 2018 | 3253 | 0.060 |
Why?
|
| Myosin Type IV | 1 | 2004 | 1 | 0.050 |
Why?
|
| Ki-67 Antigen | 1 | 2004 | 101 | 0.050 |
Why?
|
| Tissue Fixation | 1 | 2004 | 36 | 0.050 |
Why?
|
| Body Mass Index | 1 | 2010 | 1659 | 0.050 |
Why?
|
| Cell Proliferation | 3 | 2016 | 2400 | 0.050 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2004 | 69 | 0.050 |
Why?
|
| Liver Neoplasms | 1 | 2014 | 1350 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2015 | 3721 | 0.050 |
Why?
|
| Immunoenzyme Techniques | 3 | 2011 | 237 | 0.050 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2008 | 510 | 0.050 |
Why?
|
| Amino Acid Transport System y+L | 1 | 2023 | 17 | 0.050 |
Why?
|
| Microsatellite Repeats | 1 | 2004 | 229 | 0.050 |
Why?
|
| Printing, Three-Dimensional | 1 | 2024 | 83 | 0.050 |
Why?
|
| Kenya | 1 | 2023 | 58 | 0.050 |
Why?
|
| Mice, Knockout | 2 | 2023 | 3720 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 1 | 2006 | 1485 | 0.050 |
Why?
|
| Robotics | 1 | 2024 | 106 | 0.050 |
Why?
|
| Equipment Design | 1 | 2024 | 576 | 0.050 |
Why?
|
| Trans-Activators | 1 | 2005 | 676 | 0.050 |
Why?
|
| Amino Acid Metabolism, Inborn Errors | 1 | 2023 | 113 | 0.050 |
Why?
|
| Growth Disorders | 1 | 2023 | 183 | 0.050 |
Why?
|
| Texas | 1 | 2010 | 3565 | 0.050 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2023 | 155 | 0.040 |
Why?
|
| Point-of-Care Systems | 1 | 2024 | 197 | 0.040 |
Why?
|
| Hyperplasia | 1 | 2022 | 184 | 0.040 |
Why?
|
| Neoplasms | 1 | 2016 | 2857 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2006 | 2240 | 0.040 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2004 | 588 | 0.040 |
Why?
|
| Transcription Factors | 2 | 2007 | 2345 | 0.040 |
Why?
|
| Disease Models, Animal | 2 | 2023 | 4448 | 0.040 |
Why?
|
| DNA Methylation | 1 | 2007 | 1032 | 0.040 |
Why?
|
| Neoplasm Metastasis | 2 | 2018 | 689 | 0.040 |
Why?
|
| Cells, Cultured | 1 | 2006 | 2901 | 0.040 |
Why?
|
| Neoplasm Proteins | 1 | 2004 | 656 | 0.040 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2004 | 727 | 0.040 |
Why?
|
| Drosophila | 1 | 2004 | 769 | 0.040 |
Why?
|
| Aurora Kinases | 2 | 2011 | 26 | 0.040 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2021 | 228 | 0.040 |
Why?
|
| Combined Modality Therapy | 2 | 2014 | 1235 | 0.040 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2020 | 144 | 0.040 |
Why?
|
| Software | 1 | 2024 | 712 | 0.040 |
Why?
|
| Aurora Kinase A | 2 | 2011 | 35 | 0.040 |
Why?
|
| Membrane Proteins | 1 | 2007 | 1569 | 0.040 |
Why?
|
| Actinomyces | 1 | 2018 | 4 | 0.040 |
Why?
|
| Actinobacteria | 1 | 2018 | 11 | 0.040 |
Why?
|
| Bacillus | 1 | 2018 | 36 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2024 | 669 | 0.040 |
Why?
|
| Prostatic Neoplasms | 1 | 2006 | 1395 | 0.030 |
Why?
|
| Single-Cell Analysis | 1 | 2021 | 315 | 0.030 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2020 | 327 | 0.030 |
Why?
|
| Smad4 Protein | 1 | 2018 | 57 | 0.030 |
Why?
|
| Th17 Cells | 1 | 2018 | 93 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2018 | 330 | 0.030 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2018 | 382 | 0.030 |
Why?
|
| Betacoronavirus | 1 | 2020 | 285 | 0.030 |
Why?
|
| RNA, Messenger | 2 | 2016 | 2542 | 0.030 |
Why?
|
| Case-Control Studies | 2 | 2018 | 3332 | 0.030 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2018 | 293 | 0.030 |
Why?
|
| Lymphatic Metastasis | 2 | 2008 | 425 | 0.030 |
Why?
|
| Blotting, Western | 2 | 2010 | 1016 | 0.030 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2018 | 252 | 0.030 |
Why?
|
| Protein Array Analysis | 1 | 2016 | 107 | 0.030 |
Why?
|
| Colonoscopy | 1 | 2018 | 244 | 0.030 |
Why?
|
| DNA-Binding Proteins | 1 | 2004 | 1892 | 0.030 |
Why?
|
| Hydrogel, Polyethylene Glycol Dimethacrylate | 1 | 2016 | 24 | 0.030 |
Why?
|
| Neoplasms, Experimental | 1 | 2016 | 203 | 0.030 |
Why?
|
| Risk Factors | 2 | 2022 | 10638 | 0.030 |
Why?
|
| Cell Cycle | 1 | 2018 | 587 | 0.030 |
Why?
|
| Proton Pump Inhibitors | 1 | 2018 | 274 | 0.030 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2016 | 95 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 2 | 2007 | 984 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2007 | 787 | 0.030 |
Why?
|
| Infant | 1 | 2010 | 12811 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2016 | 570 | 0.030 |
Why?
|
| Cyclin E | 1 | 2014 | 32 | 0.030 |
Why?
|
| Cell Survival | 1 | 2016 | 840 | 0.030 |
Why?
|
| Gene Regulatory Networks | 1 | 2016 | 361 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2023 | 4513 | 0.030 |
Why?
|
| Prevalence | 1 | 2021 | 2623 | 0.030 |
Why?
|
| Stromal Cells | 1 | 2016 | 307 | 0.030 |
Why?
|
| Protein Biosynthesis | 1 | 2016 | 565 | 0.030 |
Why?
|
| Macrophages | 1 | 2018 | 643 | 0.030 |
Why?
|
| Young Adult | 3 | 2013 | 9707 | 0.030 |
Why?
|
| Mammary Glands, Human | 1 | 2014 | 80 | 0.030 |
Why?
|
| Organoids | 1 | 2016 | 283 | 0.020 |
Why?
|
| Graft Survival | 2 | 2005 | 455 | 0.020 |
Why?
|
| Pandemics | 1 | 2020 | 1141 | 0.020 |
Why?
|
| PAX8 Transcription Factor | 1 | 2012 | 14 | 0.020 |
Why?
|
| Base Sequence | 2 | 2007 | 2760 | 0.020 |
Why?
|
| Neoplasm Grading | 1 | 2013 | 261 | 0.020 |
Why?
|
| Keratins | 1 | 2012 | 51 | 0.020 |
Why?
|
| Paired Box Transcription Factors | 1 | 2012 | 75 | 0.020 |
Why?
|
| Antigens, Polyomavirus Transforming | 1 | 2012 | 84 | 0.020 |
Why?
|
| Risk | 1 | 2014 | 735 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 1 | 2014 | 385 | 0.020 |
Why?
|
| AC133 Antigen | 1 | 2011 | 35 | 0.020 |
Why?
|
| Molecular Sequence Data | 2 | 2007 | 3588 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2020 | 4988 | 0.020 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2012 | 169 | 0.020 |
Why?
|
| Inflammation | 1 | 2018 | 1435 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2014 | 1371 | 0.020 |
Why?
|
| Genomics | 1 | 2018 | 1549 | 0.020 |
Why?
|
| Injections, Intraperitoneal | 1 | 2010 | 66 | 0.020 |
Why?
|
| Apoptosis | 2 | 2007 | 1823 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 3714 | 0.020 |
Why?
|
| Retinal Dehydrogenase | 1 | 2009 | 11 | 0.020 |
Why?
|
| Connexin 26 | 1 | 2008 | 13 | 0.020 |
Why?
|
| Connexins | 1 | 2008 | 55 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2008 | 136 | 0.020 |
Why?
|
| GTP-Binding Proteins | 1 | 2008 | 160 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2008 | 161 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2008 | 225 | 0.020 |
Why?
|
| Genes, BRCA2 | 1 | 2007 | 48 | 0.020 |
Why?
|
| Genes, BRCA1 | 1 | 2007 | 59 | 0.020 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2007 | 120 | 0.020 |
Why?
|
| Genes, Homeobox | 1 | 2007 | 58 | 0.020 |
Why?
|
| Ovariectomy | 1 | 2007 | 166 | 0.020 |
Why?
|
| Carcinoma, Lobular | 1 | 2007 | 25 | 0.020 |
Why?
|
| Tumor Necrosis Factor Decoy Receptors | 1 | 2006 | 1 | 0.020 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 1 | 2006 | 41 | 0.020 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2006 | 96 | 0.020 |
Why?
|
| Phenotype | 1 | 2016 | 4309 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2007 | 414 | 0.020 |
Why?
|
| Karyotyping | 1 | 2006 | 313 | 0.020 |
Why?
|
| Catalytic Domain | 1 | 2006 | 151 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 2007 | 283 | 0.020 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2005 | 24 | 0.020 |
Why?
|
| Calpain | 1 | 2006 | 41 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2008 | 1008 | 0.010 |
Why?
|
| United States | 1 | 2020 | 11428 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2008 | 1538 | 0.010 |
Why?
|
| Genomic Imprinting | 1 | 2006 | 127 | 0.010 |
Why?
|
| Histone Acetyltransferases | 1 | 2005 | 224 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2005 | 622 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2007 | 755 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2005 | 435 | 0.010 |
Why?
|
| RNA, Antisense | 1 | 2004 | 35 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2009 | 776 | 0.010 |
Why?
|
| Nuclear Receptor Coactivator 3 | 1 | 2005 | 253 | 0.010 |
Why?
|
| DNA Primers | 1 | 2005 | 604 | 0.010 |
Why?
|
| Cell Size | 1 | 2004 | 79 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2013 | 5161 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2006 | 649 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 2004 | 361 | 0.010 |
Why?
|
| Creatinine | 1 | 2005 | 385 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2007 | 1206 | 0.010 |
Why?
|
| Telomere | 1 | 2004 | 207 | 0.010 |
Why?
|
| Cell Division | 1 | 2004 | 719 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2007 | 2543 | 0.010 |
Why?
|
| Cell Line | 1 | 2005 | 2566 | 0.010 |
Why?
|
| Kidney Diseases | 1 | 2005 | 482 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2005 | 1200 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2006 | 2312 | 0.010 |
Why?
|
| Drosophila Proteins | 1 | 2005 | 757 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2009 | 1759 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2005 | 1871 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2007 | 3271 | 0.010 |
Why?
|
| Time Factors | 1 | 2004 | 6172 | 0.010 |
Why?
|
| Mutation | 1 | 2007 | 5950 | 0.010 |
Why?
|
| Adolescent | 1 | 2004 | 20158 | 0.000 |
Why?
|